Stock Track | TransMedics Soars 8.86% After-Hours on Strong Q4 Results and Upbeat Guidance

Stock Track

02/25

TransMedics Group, Inc. (TMDX) saw its stock price surge 8.86% in after-hours trading on Tuesday, following the release of its fourth-quarter and full-year 2025 financial results.

The company reported Q4 2025 revenue of $160.8 million, representing 32% year-over-year growth and beating analyst expectations. Net income for the quarter reached $105.4 million, significantly boosted by an $83.8 million tax benefit related to the release of a valuation allowance on deferred tax assets. For the full year 2025, revenue grew 37% to $605.5 million.

TransMedics also provided strong guidance for fiscal year 2026, projecting revenue between $727 million and $757 million, representing 20% to 25% growth. The company highlighted increased utilization of its Organ Care System (OCS) with 5,139 U.S. cases completed in 2025, expansion of its aviation fleet to 22 owned aircraft, and recent FDA trial approvals as key growth drivers.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1192984784"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1192984784\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1192984784?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 05:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1192984784","market":"nz","top_or_hot":-1,"title":"Stock Track | TransMedics Soars 8.86% After-Hours on Strong Q4 Results and Upbeat Guidance","media":"Stock Track","content":"<p>TransMedics Group, Inc. (TMDX) saw its stock price surge 8.86% in after-hours trading on Tuesday, following the release of its fourth-quarter and full-year 2025 financial results.</p><p>The company reported Q4 2025 revenue of $160.8 million, representing 32% year-over-year growth and beating analyst expectations. Net income for the quarter reached $105.4 million, significantly boosted by an $83.8 million tax benefit related to the release of a valuation allowance on deferred tax assets. For the full year 2025, revenue grew 37% to $605.5 million.</p><p>TransMedics also provided strong guidance for fiscal year 2026, projecting revenue between $727 million and $757 million, representing 20% to 25% growth. The company highlighted increased utilization of its Organ Care System (OCS) with 5,139 U.S. cases completed in 2025, expansion of its aviation fleet to 22 owned aircraft, and recent FDA trial approvals as key growth drivers.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | TransMedics Soars 8.86% After-Hours on Strong Q4 Results and Upbeat Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | TransMedics Soars 8.86% After-Hours on Strong Q4 Results and Upbeat Guidance\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-02-25 05:33</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>TransMedics Group, Inc. (TMDX) saw its stock price surge 8.86% in after-hours trading on Tuesday, following the release of its fourth-quarter and full-year 2025 financial results.</p><p>The company reported Q4 2025 revenue of $160.8 million, representing 32% year-over-year growth and beating analyst expectations. Net income for the quarter reached $105.4 million, significantly boosted by an $83.8 million tax benefit related to the release of a valuation allowance on deferred tax assets. For the full year 2025, revenue grew 37% to $605.5 million.</p><p>TransMedics also provided strong guidance for fiscal year 2026, projecting revenue between $727 million and $757 million, representing 20% to 25% growth. The company highlighted increased utilization of its Organ Care System (OCS) with 5,139 U.S. cases completed in 2025, expansion of its aviation fleet to 22 owned aircraft, and recent FDA trial approvals as key growth drivers.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TMDX","symbol_name":"Transmedics Group","start_time":0,"source_url":"","article_id":"1192984784","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1192984784","pubTimestamp":1771968831,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"TransMedics Group, Inc. (TMDX) saw its stock price surge 8.86% in after-hours trading on Tuesday, following the release of its fourth-quarter and full-year 2025 financial results.The company reported...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TMDX":"Transmedics Group"},"translate_title":"个股追踪|TransMedics盘后飙升8.86%，得益于强劲的Q4业绩和乐观的指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TMDX":1},"content_text":"TransMedics Group, Inc. (TMDX) saw its stock price surge 8.86% in after-hours trading on Tuesday, following the release of its fourth-quarter and full-year 2025 financial results.The company reported Q4 2025 revenue of $160.8 million, representing 32% year-over-year growth and beating analyst expectations. Net income for the quarter reached $105.4 million, significantly boosted by an $83.8 million tax benefit related to the release of a valuation allowance on deferred tax assets. For the full year 2025, revenue grew 37% to $605.5 million.TransMedics also provided strong guidance for fiscal year 2026, projecting revenue between $727 million and $757 million, representing 20% to 25% growth. The company highlighted increased utilization of its Organ Care System (OCS) with 5,139 U.S. cases completed in 2025, expansion of its aviation fleet to 22 owned aircraft, and recent FDA trial approvals as key growth drivers.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}